Aim： To investigate whether oral treatment with D-004, a lipid extract of the Cuban royal palm fruit, produces antioxidant effects in the prostate tissue of normal and testosterone （T）-treated rats. Methods： In ou...Aim： To investigate whether oral treatment with D-004, a lipid extract of the Cuban royal palm fruit, produces antioxidant effects in the prostate tissue of normal and testosterone （T）-treated rats. Methods： In our first experiment, normal rats were distributed into five groups： one group treated with the vehicle and four groups treated with D-004 （100, 200, 400 or 800 mg/kg）. In our second experiment, rats were randomized into five groups： a negative control group and four T-injected groups. The latter were comprised of a positive control group treated with the vehicle, and three groups treated with D-004 （200, 400 or 800 mg/kg）. Results： In normal rats, D-004 （100-800 mg/kg） inhibited significantly and dose-dependently iron-initiated malondialdehyde （MDA） accumulation in prostate homogenates （35.7%-80.0%） vs. the controls. D-004 （200-800 mg/kg） significantly reduced baseline MDA and carbonyl groups in prostate homogenates of normal rats to approximately 80% and 50%, respectively, and totally （100%） in T-treated rats. Conclusion： Oral treatment with D-004 reduced MDA and carbonyl groups dose-dependently and markedly in normal and T-injected rats. These findings show that D-004 given at doses effective to prevent prostate hyperplasia also produces antioxidant effects in the prostate tissue.展开更多
文摘Aim： To investigate whether oral treatment with D-004, a lipid extract of the Cuban royal palm fruit, produces antioxidant effects in the prostate tissue of normal and testosterone （T）-treated rats. Methods： In our first experiment, normal rats were distributed into five groups： one group treated with the vehicle and four groups treated with D-004 （100, 200, 400 or 800 mg/kg）. In our second experiment, rats were randomized into five groups： a negative control group and four T-injected groups. The latter were comprised of a positive control group treated with the vehicle, and three groups treated with D-004 （200, 400 or 800 mg/kg）. Results： In normal rats, D-004 （100-800 mg/kg） inhibited significantly and dose-dependently iron-initiated malondialdehyde （MDA） accumulation in prostate homogenates （35.7%-80.0%） vs. the controls. D-004 （200-800 mg/kg） significantly reduced baseline MDA and carbonyl groups in prostate homogenates of normal rats to approximately 80% and 50%, respectively, and totally （100%） in T-treated rats. Conclusion： Oral treatment with D-004 reduced MDA and carbonyl groups dose-dependently and markedly in normal and T-injected rats. These findings show that D-004 given at doses effective to prevent prostate hyperplasia also produces antioxidant effects in the prostate tissue.
